Your session is about to expire
← Back to Search
IO102/IO103 + Nivolumab-Relatlimab for Melanoma
Study Summary
This trial is testing a new vaccine combo to treat melanoma, with the goal of making it safe & effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have another cancer that needs treatment or affects melanoma tests.I am fully active and can carry on all pre-disease activities without restriction.You are pregnant or breastfeeding, as confirmed by a recent pregnancy test.My melanoma is at an advanced stage and cannot be removed with surgery.I have brain metastases that were treated and I don't have symptoms.I have a measurable skin cancer lesion outside of my bones and brain.Your blood tests must show: enough red blood cells, white blood cells, and platelets; normal liver function; and good kidney function.I am a man who will use effective birth control during and for 4 months after the study, and won't donate sperm.I have had immunotherapy for advanced melanoma or another cancer, but my last dose was over 6 months ago.I have a history of autoimmune motor neuropathy.I haven't had systemic therapy for advanced melanoma, but treatments for earlier stages are okay if they were over 6 months ago.I am not detained for treatment of a mental or physical illness.You have taken high doses of steroid medication or other immune-suppressing drugs in the last two weeks. You have received a live vaccine in the last month.I am 18 years old or older.I have active hepatitis B with a high viral load.I have been diagnosed with uveal melanoma.I have active hepatitis C with a viral load over 100 IU/mL.
- Group 1: IO102/IO103, Nivolumab, and Relatlimab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is recruitment for this clinical experiment in progress?
"The trial, which was launched on June 9th 2023 and updated last on the 23rd of that same month, is currently open for patient recruitment. This information can be found online by referencing clinicaltrials.gov."
What potential harms could patients incur through exposure to IO102/IO103, Nivolumab, and Relatlimab?
"The safety of IO102/IO103, Nivolumab, and Relatlimab was estimated to be a 2 on the 1-3 scale due to this being a phase two trial. This means that there is some data indicating its safety but no evidence supporting efficacy yet."
What is the overall enrollment size for this research initiative?
"Affirmative. According to the clinicaltrials.gov database, this research endeavour was first posted on June 9th 2023 and has since been updated. It is currently seeking 43 individuals spread across 7 different sites for inclusion in the trial."
How many healthcare facilities have been appointed to execute this experiment?
"This trial is available at 7 different medical sites, such as Memorial Sloan Kettering Monmouth (Limited Protocol Activities) in Middletown, and Memorial Sloan Kettering Bergen (Limited Protocol Activities) in Montvale. Additionally, there are four other locations that qualify for this clinical research study."
Share this study with friends
Copy Link
Messenger